// App-Quantinova.ai

1178 : Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models

Researchers

Presenter

  • Asma Jabeen

Principal Investigators

  • Shiran Huang

  • John A. Hartley

  • Patrick H Van Berkel

  • Francesca Zammarchi

Medical Centers

  • ADC Therapeutics (UK) Limited, London, ENG, United Kingdom

  • Bart's Cancer Institute, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Solid malignancies

  • Colorectal Cancer

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Programmed cell death protein 1

  • Regulatory T cells

Drug/Treatment

  • ADCT301

  • Gemcitabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT04052997

  • NCT03621982

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved